Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsShenoy S, 2021 (REV) 0.76 [0.33; 1.72] 0.76[0.33; 1.72]Shenoy S, 2021 (REV)10%353NAnot evaluable clinical improvement (time to event analysis only)detailed resultsShenoy S, 2021 (REV) 1.01 [0.78; 1.30] Shinkai, 2021 (REV) 0.71 [0.47; 1.10] 0.89[0.64; 1.23]Shenoy S, 2021 (REV), Shinkai, 2021 (REV)246%936seriousnot evaluable hospital dischargedetailed resultsShenoy S, 2021 (REV) 0.94 [0.75; 1.18] 0.94[0.75; 1.18]Shenoy S, 2021 (REV)10%780NAnot evaluable hospitalizationdetailed resultsHolubar M, 2021 (REV) 8.51 [0.44; 163.99] 8.51[0.44; 163.99]Holubar M, 2021 (REV)10%149NAnot evaluable viral clearance detailed resultsHolubar M, 2021 (REV) 1.32 [0.83; 2.08] 1.32[0.83; 2.08]Holubar M, 2021 (REV)10%149NAnot evaluable viral clearance (time to event analysis only)detailed resultsHolubar M, 2021 (REV) 1.32 [0.83; 2.08] 1.32[0.83; 2.08]Holubar M, 2021 (REV)10%149NAnot evaluable serious adverse eventsdetailed resultsShinkai, 2021 (REV) 0.36 [0.02; 7.27] 0.36[0.02; 7.27]Shinkai, 2021 (REV)10%156NAnot evaluable adverse eventsdetailed resultsHolubar M, 2021 (REV) 0.48 [0.21; 1.13] Shinkai, 2021 (REV) 0.05 [0.02; 0.13] 0.16[0.02; 1.43]Holubar M, 2021 (REV), Shinkai, 2021 (REV)292%302lownot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-21 10:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons